Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
Depending on the exchange, the stock ticker may vary. For instance, on exchange Fleury SA stocks are traded under the ticker FLRYY.
When is the next Fleury SA earnings date?▼
Fleury SA is going to release the next earnings report on May 07, 2026.
What were Fleury SA earnings last quarter?▼
FLRYY earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.02 USD resulting in a +42.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
How many employees does Fleury SA have?▼
As of April 04, 2026, the company has 16,700 employees.
In which sector is Fleury SA located?▼
Fleury SA operates in the Healthcare sector.
When did Fleury SA complete a stock split?▼
The last stock split for Fleury SA was on June 13, 2023 with a ratio of 21:20.